Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease

Background Inhibition of bromodomain and extra-terminal (BET) proteins can modulate lipoprotein and inflammatory factors that mediate atherosclerosis. The impact of the BET inhibitor, apabetalone, on cardiovascular events is unknown. Objective Our objective was to investigate the impact of apabetalo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of cardiovascular drugs : drugs, devices, and other interventions devices, and other interventions, 2018-04, Vol.18 (2), p.109-115
Hauptverfasser:	Nicholls, Stephen J., Ray, Kausik K., Johansson, Jan O., Gordon, Alan, Sweeney, Michael, Halliday, Chris, Kulikowski, Ewelina, Wong, Norman, Kim, Susan W., Schwartz, Gregory G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticholesteremic Agents - therapeutic use Apolipoproteins Atherosclerosis Atherosclerosis - metabolism C-Reactive Protein - metabolism Cardiology Cardiovascular disease Cardiovascular Diseases - chemically induced Cardiovascular Diseases - metabolism Cardiovascular System - drug effects Cardiovascular System - metabolism Cholesterol Cholesterol, HDL Clinical Trials as Topic Coronary Artery Disease - drug therapy Coronary Artery Disease - metabolism Coronary vessels Diabetes Female Health risk assessment Heart attacks Humans Lipids Lipoproteins Male Medicine Medicine & Public Health Middle Aged Original Research Article Pharmacology/Toxicology Pharmacotherapy Proteins Proteins - antagonists & inhibitors Risk Statins Statistical analysis Studies Ultrasonic imaging
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!